Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | CSF1R | P07333 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198107 | 1.00 | MAPK14 (0.64) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL13198114 | 0.99 | MAPK14 (0.65) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL4962163 | 0.86 | PRMT3 (0.70) | NPC1RAB9APRMT3SMN1; SMN2EPHX2 | |
| SCHEMBL4962243 | 0.86 | PRMT3 (0.70) | NPC1RAB9APRMT3SMN1; SMN2EPHX2 | |
| SCHEMBL29450608 | 0.83 | POLB (0.60) | KDRNPC1RAB9APRMT3TSHR | |
| SCHEMBL2893609 | 0.81 | IMPDH2 (0.64) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL13198113 | 0.81 | POLB (0.56) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL29450622 | 0.81 | KMT2A (0.54) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL13198118 | 0.80 | MEN1 (0.59) | MAPK14LCKCSF1RKDRNPC1 | |
| SCHEMBL13198091 | 0.80 | MAPK14 (0.53) | MAPK14LCKCSF1RKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | MAPK14 146/4885LCK 140/4885CSF1R 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.